Shanghai Cancer Center, Tencent to streamline cancer treatment with AI

Multinational investment holding conglomerate Tencent is working with the Shanghai Cancer Center to establish an AI-based, big data laboratory to streamline the cancer treatment process, according to a report by Shine, a digital news organization under Shanghai Daily.

Using AI, the entities hope to develop a clinical research and treatment platform, improve medical record management, allow for early screening for people at high risk for cancer, assign patients to appropriate experts and improve follow-up management for discharged patients, according to the report. The effort is aimed at using AI to achieve more precise medicine, better patient matching for new drug trials and a streamlined cancer treatment process.

“Many patients who come to my clinic don’t need surgery or their condition was outside my specialty, so the AI system requires patients to upload detailed information and looks for keywords, in order to avoid mismatching,” Wu Jiong, MD, PhD, a breast cancer surgeon at Shanghai Cancer Center, said in the report.

Tencent has announced several healthcare-based partnerships within the last several months. In January, the company announced a collaboration with Merck KGaA, a German-based pharmaceutical, life sciences and technology company, to leverage AI and big data to increase disease awareness and provide more accessible healthcare services. Last year, Tencent partnered with healthcare firm Medopad to train systems to use AI to better diagnose Parkinson’s disease.

To read the full report, click the link below.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.